Mode
Text Size
Log in / Sign up
Phase 3 Completed N=2,221 Randomized Single-blind Treatment

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Source: ClinicalTrials.gov NCT00551616 ↗
Enrolled (actual)
2,221
Serious AEs
0.3%
Results posted
Mar 2022
Primary outcomePrimary: Number of Participants With Pregnancy — 20; 30 Participants
◆ Published Evidence
Highly cited
526citations · ~33 / year
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
Lancet (London, England) · 2010 · High-confidence link

Summary

The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.

Linked Publications

  • Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
    Lancet (London, England) · 2010 · 526 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Pregnancy
20; 30
SECONDARY
Actual Pregnancy Rate Compared to Expected Pregnancy Rate
15; 22; 47; 46 <0.001 sig
SECONDARY
Menstrual Bleeding Patterns
2.1; -1.2

Eligibility Criteria

Inclusion Criteria

  • women 16 or older in UK(except Northern Ireland) sites, 17 years or more in Northern Ireland (UK) and 18 years or more in Ireland and US
  • present within 120 hours of unprotected intercourse
  • regular menstrual cycles
  • No current use of hormonal contraception
  • Willing to not use hormonal methods of contraception until study completion
  • At least one complete menstrual cycle (2 menses) post miscarriage, delivery or abortion
  • For women who present more than 72 hours after intercourse, decline the insertion of an Intra Uterine Device for emergency contraception
  • Able to provide informed consent
  • Willing to abstain from further acts of unprotected intercourse until study completion

Exclusion Criteria

  • One or more acts of unprotected intercourse more than 120 hours
  • current or recent use of hormonal methods of contraception
  • currently pregnant or breastfeeding
  • tubal ligation or current use of IUD
  • Use of hormonal emergency contraception since last menstrual period
  • Current use of IUD
  • Tubal ligation
  • Partner with a vasectomy
  • Unsure about the date of the last menstrual period
  • Severe asthma insufficiently controlled by oral glucocorticoid
  • Hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00551616) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search